Suppr超能文献

功能性垂体腺瘤——当前的治疗选择与新兴药物疗法

Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies.

作者信息

Varlamov Elena V, McCartney Shirley, Fleseriu Maria

机构信息

Oregon Health & Science University, Oregon, USA.

出版信息

Eur Endocrinol. 2019 Apr;15(1):30-40. doi: 10.17925/EE.2019.15.1.30. Epub 2019 Apr 12.

Abstract

Pituitary adenomas are benign tumours comprising approximately 16% of all primary cranial neoplasms. Functioning pituitary adenomas (prolactinomas, somatotroph, corticotroph, thyrotroph and rarely gonadotroph adenomas) cause complex clinical syndromes and require prompt treatment to reduce associated morbidity and mortality. Treatment approaches include transsphenoidal surgery, medical therapy and radiation. Medical therapy is the primary therapy for prolactinomas, and surgery by a skilled neurosurgeon is the first-line approach for other functioning pituitary adenomas. A multimodal treatment is frequently necessary to achieve biochemical and clinical control, especially, when surgery is not curative or when medical therapy fails. Several emerging, novel, medical treatments for acromegaly, Cushing's disease and prolactinomas are in phase II and III clinical trials and may become effective additions to the current drug armamentarium. The availability of various management options will allow an individualised treatment approach based on the unique tumour type, clinical situation and patient preference.

摘要

垂体腺瘤是良性肿瘤,约占所有原发性颅脑肿瘤的16%。功能性垂体腺瘤(泌乳素瘤、生长激素瘤、促肾上腺皮质激素瘤、促甲状腺激素瘤以及罕见的促性腺激素瘤)会引发复杂的临床综合征,需要及时治疗以降低相关的发病率和死亡率。治疗方法包括经蝶窦手术、药物治疗和放射治疗。药物治疗是泌乳素瘤的主要治疗方法,而由经验丰富的神经外科医生进行的手术则是其他功能性垂体腺瘤的一线治疗方法。为实现生化和临床控制,通常需要采取多模式治疗,尤其是在手术无法治愈或药物治疗失败的情况下。几种针对肢端肥大症、库欣病和泌乳素瘤的新兴、新型药物治疗正处于II期和III期临床试验阶段,可能会成为当前药物库中的有效补充。多种治疗选择的可用性将使基于独特肿瘤类型、临床情况和患者偏好的个体化治疗方法成为可能。

相似文献

1
Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies.
Eur Endocrinol. 2019 Apr;15(1):30-40. doi: 10.17925/EE.2019.15.1.30. Epub 2019 Apr 12.
2
Medical treatment of functional pituitary adenomas, trials and tribulations.
J Neurooncol. 2024 Jun;168(2):197-213. doi: 10.1007/s11060-024-04670-x. Epub 2024 May 18.
4
Medical approach to pituitary tumors.
Handb Clin Neurol. 2014;124:303-16. doi: 10.1016/B978-0-444-59602-4.00020-4.
5
Galanin in human pituitary adenomas: frequency and clinical significance.
Clin Endocrinol (Oxf). 2002 Mar;56(3):397-403. doi: 10.1046/j.1365-2265.2002.01486.x.
6
Glycoprotein hormone alpha-subunit secretion in prolactinomas and in non-functioning adenomas: relation with the tumour size.
Clin Endocrinol (Oxf). 1994 Aug;41(2):177-84. doi: 10.1111/j.1365-2265.1994.tb02527.x.
8
Surgical management of pituitary adenomas.
Singapore Med J. 2002 Jun;43(6):318-23.
9
Microsurgical therapy of pituitary adenomas.
Endocrine. 2018 Jan;59(1):72-81. doi: 10.1007/s12020-017-1458-3. Epub 2017 Oct 24.
10
Management of hormone-secreting pituitary adenomas.
Neuro Oncol. 2017 Jun 1;19(6):762-773. doi: 10.1093/neuonc/now130.

引用本文的文献

1
Challenges and opportunities for new intraoperative optical techniques in the surgical treatment of pituitary adenomas: a review.
J Biomed Opt. 2025 Aug;30(8):080901. doi: 10.1117/1.JBO.30.8.080901. Epub 2025 Aug 13.
2
Cellular mechanisms of hormone secretion in neuroendocrine tumors: what goes wrong?
Front Cell Dev Biol. 2025 Jul 1;13:1527083. doi: 10.3389/fcell.2025.1527083. eCollection 2025.
3
Endocrine cancer organoids in basic and translational medical research.
Sci China Life Sci. 2025 Jun 5. doi: 10.1007/s11427-024-2888-8.
5
Investigating Endocrine Causes in Fluid Non-responsive Hypotension: An Interesting Case of a Pituitary Macroadenoma.
Cureus. 2024 Dec 16;16(12):e75843. doi: 10.7759/cureus.75843. eCollection 2024 Dec.
7
Clinical features of pituitary carcinoma: analysis based on a case report and literature review.
Front Endocrinol (Lausanne). 2024 Oct 31;15:1440247. doi: 10.3389/fendo.2024.1440247. eCollection 2024.
8
A Peculiar Case of Cabergoline Response to a Non-functioning Cystic Pituitary Adenoma in a Young Adult Male.
Cureus. 2024 Aug 27;16(8):e67927. doi: 10.7759/cureus.67927. eCollection 2024 Aug.
9
Neuro-ophthalmic evaluation and management of pituitary disease.
Eye (Lond). 2024 Aug;38(12):2279-2288. doi: 10.1038/s41433-024-03187-x. Epub 2024 Jul 22.
10
Medical treatment of functional pituitary adenomas, trials and tribulations.
J Neurooncol. 2024 Jun;168(2):197-213. doi: 10.1007/s11060-024-04670-x. Epub 2024 May 18.

本文引用的文献

1
2
Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
Nat Commun. 2018 Aug 9;9(1):3171. doi: 10.1038/s41467-018-05275-5.
3
PATHOGENESIS OF CUSHING DISEASE: AN UPDATE ON THE GENETICS OF CORTICOTROPINOMAS.
Endocr Pract. 2018 Oct 2;24(10):907-914. doi: 10.4158/EP-2018-0111. Epub 2018 Aug 7.
4
The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening.
J Endocr Soc. 2018 Jul 11;2(8):965-969. doi: 10.1210/js.2018-00139. eCollection 2018 Aug 1.
6
A Consensus Statement on acromegaly therapeutic outcomes.
Nat Rev Endocrinol. 2018 Sep;14(9):552-561. doi: 10.1038/s41574-018-0058-5.
10
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly.
Eur J Endocrinol. 2018 Aug;179(2):97-108. doi: 10.1530/EJE-18-0138. Epub 2018 May 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验